Objective： To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection（STS） as one adjuvant therapy for treating unstable angina pectoris（UAP）. Methods： Randomized contro...Objective： To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection（STS） as one adjuvant therapy for treating unstable angina pectoris（UAP）. Methods： Randomized controlled trials（RCTs） of UAP treated by STS were searched in the China National Knowledge Infrastructure Database（CNKI）, VIP Database for Chinese Technical Periodicals（VIP）, Wanfang Database, the Chinese Biomedical Literature Database（CBM）, Web of Science, the Cochrane Library, Embase, and Pub Med, which from inception to January, 2016. The Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5.3 software was used to conduct the metaanalysis. Results： The results showed that 17 RCTs involving 1,372 patients were included. The meta-analysis indicated that the combined use of STS and Western medicine（WM） in the treatment of UAP can obviously improve the total effective rate [risk ratio（RR）=1.31, 95% confidence interval（CI）（1.24,1.39）, P〈0.0001], and the total effective rate of electrocardiogram [RR=1.43, 95% CI（1.30,1.56）, P〈0.0001], decrease the level of CRP [mean difference（MD）=–3.06, 95%CI（–3.85, –2.27）, P〈0.00001], fibrinogen [MD=–1.03, 95% CI（–1.16, –0.89）, P〈0.00001], and whole blood high shear viscosity [MD=–0.70, 95% CI（–0.92, –0.49）, P〈0.00001]. Additionally, the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57, 95% CI（1.28, 9.94）, P〈0.05]. Conclusions： Compared with WM, the combined use of STS was more effective.展开更多
OBJECTIVE: To explore the effects of Tanshinone combined with western medicine on clinical symptoms and cardiac function in patients with acute heart failure. METHODS: The medical records of 96 patients with acute hea...OBJECTIVE: To explore the effects of Tanshinone combined with western medicine on clinical symptoms and cardiac function in patients with acute heart failure. METHODS: The medical records of 96 patients with acute heart failure were randomly divided into 2 groups(48 cases in observation group and 48 cases in control group). The control group was treated with conventional western medicine, and the observation group was treated with Tanshinone IIA sulfonic acid natrium on the basis of western medicine. The traditional Chinese medicine(TCM) syndromes scores before and after treatment(after 28 d of treatment), clinical efficacy, and cardiac echocardiographic indexes and serum biochemical indicators before and after treatment were observed in the 2 groups. RESULTS: After treatment, the scores of TCM syndromes in the 2 groups were significantly decreased(P < 0.05), and the change in observation group was significantly greater than that in control group(P < 0.05). The total clinical effective rate in observation group was significantly higher than that in control group(91.67% vs 75.00%)(P < 0.05). After treatment, the echocardiographic indexes of left ventricular end-diastolic diameter(LVEDD) and left ventricular end-systolic diameter(LVESD) values were significantly reduced in the 2 groups while the left ventricular ejection fraction(LVEF) and stroke volume(SV) value were significantly increased, and the changes in observation group were significantly larger than those in control group(P < 0.05). After treatment, the levels of serum nuclear factor-kappaB(NF-KB), interleukin-1β(IL-1β) and N-terminal pro-brain natriuretic peptide(NT-proBNP) were significantly decreased in the 2 groups(P < 0.05), while the 6-keto-prostaglandin F1α(6-ketoPGF1α) level was significantly increased. And the changes in observation group were significantly greater than those in control group(P < 0.05). CONCLUSION: Tanshinone combined with western medicine can significantly improve the clinical symptoms of patients with acute heart failure, improve cardiac function, reduce the myocardial damage degree, and effectively reduce the risk of short-term recurrence and death, and it has exact clinical efficacy.展开更多
目的观察丹参酮ⅡA磺酸钠注射液对病毒性心肌炎模型小鼠冠状动脉血管内皮损伤的保护作用并探讨其机制。方法取Balb/c小鼠60只,选取其中40只,采用连续3 d腹腔接种柯萨奇病毒B3(CVB3Nancy株)的方法建立小鼠病毒性心肌炎模型,10 d后随机分...目的观察丹参酮ⅡA磺酸钠注射液对病毒性心肌炎模型小鼠冠状动脉血管内皮损伤的保护作用并探讨其机制。方法取Balb/c小鼠60只,选取其中40只,采用连续3 d腹腔接种柯萨奇病毒B3(CVB3Nancy株)的方法建立小鼠病毒性心肌炎模型,10 d后随机分为病毒性心肌炎模型组和丹参组,另20只作空白对照。其中丹参组按2.0 m L/(kg·d)尾静脉注射丹参酮ⅡA磺酸钠注射液治疗7 d,心肌炎模型组和空白对照组注射等体积0.9%氯化钠注射液。取治疗前后静脉血和小鼠心脏并分离出冠状动脉血管,采用酶联免疫吸附法检验小鼠血清肌酸激酶(CK)、肌酸激酶同工酶MB(CK-MB)、乳酸脱氢酶(LDH)、氧化物歧化酶(SOD)及丙二醛(MDA)。采用免疫组化染色检测冠状动脉血管内皮诱导型一氧化氮合酶(i NOS)的表达,双抗体夹心法测定冠状动脉血管内皮因子(VEGF)表达,反转录-聚合酶链反应(RT-PCR)检测冠状动脉血管VEGF m RNA。结果治疗后,丹参组血清CK、CK-MB、LDH及MDA较治疗前和心肌炎模型组明显降低、SOD明显提高(P<0.05);冠状动脉i NOS阳性表达减少,与治疗前和心肌炎模型组比较差异有统计学意义(P<0.05);VEGF及VEGF m RN高表达并高于心肌炎模型组和空白对照组,与治疗前、空白对照组和心肌炎模型组比较差异有统计学意义(P<0.05)。结论丹参酮ⅡA磺酸钠注射液可减轻CVB3 Nancy株对Balb/c小鼠冠状动脉血管内皮造成的损伤,对病毒性心肌炎模型心肌具有保护作用。展开更多
基金Supported by the National Natural Science Foundation of China(No.81473547 and No.81673829)
文摘Objective： To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection（STS） as one adjuvant therapy for treating unstable angina pectoris（UAP）. Methods： Randomized controlled trials（RCTs） of UAP treated by STS were searched in the China National Knowledge Infrastructure Database（CNKI）, VIP Database for Chinese Technical Periodicals（VIP）, Wanfang Database, the Chinese Biomedical Literature Database（CBM）, Web of Science, the Cochrane Library, Embase, and Pub Med, which from inception to January, 2016. The Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5.3 software was used to conduct the metaanalysis. Results： The results showed that 17 RCTs involving 1,372 patients were included. The meta-analysis indicated that the combined use of STS and Western medicine（WM） in the treatment of UAP can obviously improve the total effective rate [risk ratio（RR）=1.31, 95% confidence interval（CI）（1.24,1.39）, P〈0.0001], and the total effective rate of electrocardiogram [RR=1.43, 95% CI（1.30,1.56）, P〈0.0001], decrease the level of CRP [mean difference（MD）=–3.06, 95%CI（–3.85, –2.27）, P〈0.00001], fibrinogen [MD=–1.03, 95% CI（–1.16, –0.89）, P〈0.00001], and whole blood high shear viscosity [MD=–0.70, 95% CI（–0.92, –0.49）, P〈0.00001]. Additionally, the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57, 95% CI（1.28, 9.94）, P〈0.05]. Conclusions： Compared with WM, the combined use of STS was more effective.
文摘OBJECTIVE: To explore the effects of Tanshinone combined with western medicine on clinical symptoms and cardiac function in patients with acute heart failure. METHODS: The medical records of 96 patients with acute heart failure were randomly divided into 2 groups(48 cases in observation group and 48 cases in control group). The control group was treated with conventional western medicine, and the observation group was treated with Tanshinone IIA sulfonic acid natrium on the basis of western medicine. The traditional Chinese medicine(TCM) syndromes scores before and after treatment(after 28 d of treatment), clinical efficacy, and cardiac echocardiographic indexes and serum biochemical indicators before and after treatment were observed in the 2 groups. RESULTS: After treatment, the scores of TCM syndromes in the 2 groups were significantly decreased(P < 0.05), and the change in observation group was significantly greater than that in control group(P < 0.05). The total clinical effective rate in observation group was significantly higher than that in control group(91.67% vs 75.00%)(P < 0.05). After treatment, the echocardiographic indexes of left ventricular end-diastolic diameter(LVEDD) and left ventricular end-systolic diameter(LVESD) values were significantly reduced in the 2 groups while the left ventricular ejection fraction(LVEF) and stroke volume(SV) value were significantly increased, and the changes in observation group were significantly larger than those in control group(P < 0.05). After treatment, the levels of serum nuclear factor-kappaB(NF-KB), interleukin-1β(IL-1β) and N-terminal pro-brain natriuretic peptide(NT-proBNP) were significantly decreased in the 2 groups(P < 0.05), while the 6-keto-prostaglandin F1α(6-ketoPGF1α) level was significantly increased. And the changes in observation group were significantly greater than those in control group(P < 0.05). CONCLUSION: Tanshinone combined with western medicine can significantly improve the clinical symptoms of patients with acute heart failure, improve cardiac function, reduce the myocardial damage degree, and effectively reduce the risk of short-term recurrence and death, and it has exact clinical efficacy.
文摘目的观察丹参酮ⅡA磺酸钠注射液对病毒性心肌炎模型小鼠冠状动脉血管内皮损伤的保护作用并探讨其机制。方法取Balb/c小鼠60只,选取其中40只,采用连续3 d腹腔接种柯萨奇病毒B3(CVB3Nancy株)的方法建立小鼠病毒性心肌炎模型,10 d后随机分为病毒性心肌炎模型组和丹参组,另20只作空白对照。其中丹参组按2.0 m L/(kg·d)尾静脉注射丹参酮ⅡA磺酸钠注射液治疗7 d,心肌炎模型组和空白对照组注射等体积0.9%氯化钠注射液。取治疗前后静脉血和小鼠心脏并分离出冠状动脉血管,采用酶联免疫吸附法检验小鼠血清肌酸激酶(CK)、肌酸激酶同工酶MB(CK-MB)、乳酸脱氢酶(LDH)、氧化物歧化酶(SOD)及丙二醛(MDA)。采用免疫组化染色检测冠状动脉血管内皮诱导型一氧化氮合酶(i NOS)的表达,双抗体夹心法测定冠状动脉血管内皮因子(VEGF)表达,反转录-聚合酶链反应(RT-PCR)检测冠状动脉血管VEGF m RNA。结果治疗后,丹参组血清CK、CK-MB、LDH及MDA较治疗前和心肌炎模型组明显降低、SOD明显提高(P<0.05);冠状动脉i NOS阳性表达减少,与治疗前和心肌炎模型组比较差异有统计学意义(P<0.05);VEGF及VEGF m RN高表达并高于心肌炎模型组和空白对照组,与治疗前、空白对照组和心肌炎模型组比较差异有统计学意义(P<0.05)。结论丹参酮ⅡA磺酸钠注射液可减轻CVB3 Nancy株对Balb/c小鼠冠状动脉血管内皮造成的损伤,对病毒性心肌炎模型心肌具有保护作用。
